Geoffrey Shapiro
Senior Vice President, Developmental Therapeutics · Mass General Brigham
Credentials: · · · ·
History
- Present
Center for DNA Damage and Repair · Mass General Brigham
- Present
- 1991–1993
- 1988–1991
Beth Israel Hospital
1984–1988
Research
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
New England Journal of Medicine · 2010 · 3,649 citations
Crizotinib in ROS1-rearranged non-small-cell lung cancer
New England Journal of Medicine · 2014 · 1,560 citations
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
New England Journal of Medicine · 2020 · 1,421 citations
43 papers
36 papers
26 papers
25 papers
25 papers
21 papers
19 papers
- CF
18 papers
Grants
- 2026–2031
Macrophage-Directed Strategies for BRCA-Associated Breast Cancer
National Cancer Institute · R01
PI · $772.2K · Brigham and Women's Hospital
- 2013–2030
Dana Farber/Harvard Cancer Center Specialized Program of Research Excellence in Breast Cancer
National Cancer Institute · P50
PI · $12M · Dana-Farber Cancer Inst
- 2024–2029
Targeting Replication Stress and DNA Damage Response in Uterine Cancer
National Cancer Institute · P01
Project lead · $1.4M · Dana-Farber Cancer Inst
- 2023–2028
Genetically Engineered Mouse Model to Improve Therapy of NUT Carcinoma
National Cancer Institute · R01
PI · $2.6M · Brigham and Women's Hospital
Clinical trials
- 2023–2028
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
- 2023–2028
Principal investigator · Recruiting · Phase 1
National Cancer Institute (NCI)
- 2020
Principal investigator · Withdrawn · Phase 1, Phase 2
National Cancer Institute (NCI)
- 2018–2021
Principal investigator · Completed · Phase 1
Dana-Farber Cancer Institute